Graft-versus-Host Disease Treatment Market By Disease Type (Acute Graft-versus-Host Disease, Chronic Graft-versus-Host Disease); By Treatment Modality (Systemic Corticosteroids and Conventional Immunosuppressants, Targeted Oral Therapies, Infused Biologics, Cellular Therapies, Extracorporeal Photopheresis, Other Salvage Therapies); By Line of Therapy (First-Line Treatment, Second-Line Treatment, Third-Line and Later-Line Treatment); By Route of Administration (Oral, Intravenous, Extracorporeal); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Other Institutional Channels); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Graft-versus-Host Disease Treatment Market: Steroid Failure, Chronic Disease Persistence, and Specialist Drug Launches Drive Commercial Demand

The Global Graft-versus-Host Disease Treatment Market was valued at USD 3.17 billion in 2025 and is projected to reach USD 5.29 billion by 2032, growing at a CAGR of 7.6%, according to Strategic Market Research.

 

The graft-versus-host disease treatment market is concentrated among patients who develop clinically significant immune complications after allogeneic hematopoietic cell transplantation. Allogeneic transplant activity defines the population at risk, but treatment revenue depends on progression into moderate or severe disease, inadequate corticosteroid response, chronic organ involvement, treatment duration, and access to second- or later-line therapy.

 

Systemic medicines account for most commercial activity. Oral targeted drugs generate recurring prescription demand, infused antibodies create hospital buy-and-bill revenue, and cellular products produce high-value multi-dose treatment courses. Extracorporeal photopheresis remains an important hospital-based alternative, but it is an apheresis procedure rather than surgery and serves as a supporting pathway alongside systemic treatment.

 

Transplant hematologists and multidisciplinary transplant teams control treatment selection. Hospital pharmacies manage infused and cellular therapies, specialty pharmacies distribute oral products, and public or private payers influence use through formulary placement, prior authorization, health technology assessment, and negotiated pricing.

 

U.S. Transplant Activity Creates a Defined Annual Risk Pool

U.S. transplant centers reported 22,579 hematopoietic cell transplants in 2024. The total included 6,646 unrelated and 3,756 related allogeneic procedures, producing an annual allogeneic risk base of 10,402 transplants. Autologous procedures are not included in the principal GVHD treatment opportunity because patients receive their own cells rather than donor cells.

Acute GVHD develops in approximately 30%–50% of allogeneic transplant recipients, although incidence varies with donor matching, graft source, conditioning regimen, patient age, and prophylaxis. Applying that range to 10,402 U.S. allogeneic procedures indicates approximately 3,100–5,200 potential acute cases arising from the 2024 transplant cohort. The result is an analyst calculation rather than a published diagnosed-patient count.

An older clinical estimate placed annual U.S. acute-GVHD incidence at approximately 5,500 patients. That figure remains widely cited, but current transplant activity supports using it as a directional benchmark rather than a precise 2026 patient total. Acute disease incidence changes as transplant volumes, donor selection, post-transplant cyclophosphamide use, and other preventive practices evolve.

Chronic GVHD contributes a larger long-duration treatment population. A U.S. claims-based analysis projected 14,017 prevalent chronic-GVHD patients in 2016. Within three years of allogeneic transplantation, 42% developed chronic disease; 71% of diagnosed patients progressed to a second treatment line and 47% reached a third line. Those treatment transitions explain why chronic GVHD supports several branded products despite its orphan-disease status.

The acute annual-incidence estimate and chronic prevalence estimate should not be added to create a single U.S. patient total. Acute data measure newly developing cases, while chronic prevalence includes patients who may remain under treatment for several years.

 

European Demand Is Better Measured Through Transplant Activity Than Commercial Prevalence Models

The European Society for Blood and Marrow Transplantation received reports of 47,204 hematopoietic cell transplants in 2024, including 21,023 allogeneic procedures. Allogeneic activity increased by 2.6% from 2023 and reached the highest level recorded by the survey. The reporting network included 688 centers across 53 countries, providing a large specialist infrastructure for GVHD prevention, diagnosis, systemic treatment, infusions, and extracorporeal photopheresis.

Unrelated donors accounted for 56% of reported allogeneic procedures in 2024, while HLA-identical siblings represented 25% and haploidentical donors 19%. Donor mix has direct treatment relevance because unrelated and mismatched transplantation can carry a higher GVHD risk than closely matched sibling transplantation.

Applying a 30%–50% acute-GVHD incidence range to the 21,023 allogeneic procedures reported by EBMT produces an indicative annual range of approximately 6,300–10,500 acute cases across the reporting region. The calculation does not represent a published EBMT patient count and should not be interpreted as treated-drug volume because disease severity, survival, steroid response, and reimbursement reduce the eligible population.

Commercial epidemiology estimates have placed Germany, Italy, Spain, and the UK at different annual case levels, including approximately 8,200 cases in Germany. EBMT, however, reports transplant procedures, centers, donor types, and indications rather than standardized annual GVHD prevalence totals for those countries. Country estimates derived from commercial forecasting models should therefore not be presented as EBMT registry statistics.

Chronic GVHD incidence is commonly reported between 30% and 70% among patients surviving beyond the early post-transplant period. A multicenter severity analysis found that 25% of chronic cases were mild, 46% moderate, and 29% severe at onset. Moderate and severe disease carries the greatest commercial relevance because patients are more likely to require systemic treatment, extended immunosuppression, organ-specific care, and several treatment lines.

 

Inadequate Steroid Response Defines the Branded Treatment Population

Systemic corticosteroids remain the initial treatment for clinically significant acute and chronic GVHD. Methylprednisolone is commonly used in acute disease, while prednisone-based regimens remain established in chronic disease. Calcineurin inhibitors, methotrexate, mycophenolate mofetil, sirolimus, antithymocyte globulin, and post-transplant cyclophosphamide are used across prophylaxis and treatment pathways according to donor type, transplant protocol, and center practice.

Only about 40%–50% of patients with moderate or severe acute GVHD respond adequately to first-line systemic corticosteroids. Progression after several days, absence of improvement, incomplete response, steroid dependence, or unacceptable toxicity moves patients into second-line treatment. Infection risk also increases as transplant teams layer additional immunosuppression onto an already vulnerable immune system.

Generic corticosteroids generate limited revenue despite their central clinical role. Branded value is concentrated after steroid failure, where hospitals and payers must choose among targeted oral drugs, infused antibodies, cellular therapy, extracorporeal photopheresis, and less standardized salvage regimens.

 

Ruxolitinib and Ryoncil Define the Acute-GVHD Branded Segment

Ruxolitinib established targeted treatment for steroid-refractory acute GVHD after receiving FDA approval in 2019 for patients aged 12 years and older. Oral administration supports continued treatment without the repeated hospital attendance required for extracorporeal photopheresis or infusion-based rescue therapy. Familiarity across acute and chronic GVHD also gives transplant centers one product that can be used at different stages of post-transplant disease.

Remestemcel-L-rknd, marketed as Ryoncil by Mesoblast, added a pediatric cellular-therapy pathway in December 2024. The FDA approved Ryoncil for steroid-refractory acute GVHD in patients two months of age and older, making it the first FDA-approved mesenchymal stromal cell therapy. The approval study included 54 pediatric patients and recorded 38 responses at Day 28, comprising 16 complete and 22 partial responses.

Ryoncil requires an initial series of eight intravenous infusions over four weeks, with further doses possible according to response. Hospital pharmacy preparation, infusion scheduling, cold-chain management, reimbursement approval, and center onboarding make treatment operationally more complex than an oral prescription, but the defined multi-infusion course supports high revenue per patient.

Mesoblast recorded $48.7 million in Ryoncil net product sales during the six months ended December 2025 after launching in 2025. The company reported a 93% gross margin for the period, although early launch economics should not be treated as a stable margin benchmark for the broader cellular-therapy sector.

Pediatric transplant activity is concentrated in a limited number of hospitals, allowing Mesoblast to focus commercial coverage on specialist accounts rather than a broad prescriber network. Adult steroid-refractory acute GVHD offers a larger potential population, but expansion would require evidence supporting cellular therapy against ruxolitinib, extracorporeal photopheresis, antithymocyte globulin, and center-specific salvage treatment.

 

Chronic GVHD Supports Several Mechanisms and Treatment Lines

Chronic GVHD can affect the skin, mouth, eyes, lungs, liver, gastrointestinal tract, joints, fascia, and genital tissues. Multi-organ disease and fibrosis can require years of treatment, creating recurring demand for prescriptions, infusions, infection prophylaxis, pulmonary monitoring, rehabilitation, and organ-specific supportive care.

Ibrutinib became the first FDA-approved drug for chronic GVHD after failure of systemic therapy. Ruxolitinib entered after failure of one or two systemic treatments, while belumosudil and axatilimab were positioned after at least two previous therapies. Treatment selection now depends on prior exposure, affected organs, blood counts, infection history, fibrosis, tolerability, administration preference, and the need to reduce corticosteroid use.

Belumosudil, marketed as Rezurock, provides a once-daily oral option for adults and adolescents aged 12 years and older. EMA-authorized use covers patients for whom other available treatments provide limited benefit, are unsuitable, or have been exhausted. In the main study, 57 of 78 patients receiving the once-daily regimen responded during the first six months. European authorization expands the eligible geography, but national pricing and reimbursement decisions will determine actual uptake.

Axatilimab, marketed as Niktimvo by Incyte and developed with Syndax, targets chronic GVHD after at least two previous systemic lines. FDA approval covers adults and pediatric patients weighing at least 40 kilograms. The recommended regimen is an intravenous infusion every two weeks, creating recurring hospital administration and product revenue.

Niktimvo produced $151.6 million in net product revenue during 2025 after its first-quarter U.S. launch. Strong first-year uptake confirms that refractory chronic GVHD can support substantial revenue even when the approved population is limited to later treatment lines. Treatment duration, repeat dosing, specialist access, and premium pricing compensate for low unit volume.

Earlier-line studies could expand the axatilimab opportunity, but transplant centers and payers will expect improvements in durable response, organ function, steroid reduction, or treatment failure before adding another premium product to established regimens.

 

Oral Drugs Compete with Extracorporeal Photopheresis for Hospital Capacity

Extracorporeal photopheresis remains important in steroid-refractory and steroid-dependent GVHD, particularly when the skin and other chronic organ systems are involved. Treatment requires apheresis equipment, trained staff, vascular access, and repeated hospital visits.

Oral drugs compete partly through convenience and partly through reduced service use. A NICE resource model estimated that ruxolitinib adoption in acute GVHD could replace approximately 1,700 photopheresis infusions and release 4,200 nursing hours annually by the fifth year. The estimate applies to England and should not be extrapolated directly to other countries, but it illustrates the hospital-capacity argument behind oral treatment adoption.

Payers increasingly evaluate total treatment burden rather than acquisition cost alone. Reduced photopheresis sessions, fewer hospital visits, lower nursing use, improved steroid tapering, and fewer treatment switches can support reimbursement even when branded drug costs exceed those of corticosteroids.

 

North America Leads Commercialization While European Access Remains Country-Specific

North America has the strongest current commercial infrastructure. The United States combines more than 10,000 annual allogeneic transplant procedures, several FDA-approved GVHD therapies, specialist hospital networks, product-specific billing codes, and publicly disclosed sales for recent launches. Niktimvo and Ryoncil generated more than $200 million in combined disclosed 2025-period revenue.

CMS established HCPCS code J9038 for axatilimab, effective April 2025, and a product-specific code for Ryoncil effective October 2025. Coding improves claims identification and hospital billing, although it does not guarantee coverage or eliminate prior authorization.

Europe has a larger regional allogeneic procedure base but a fragmented access pathway. Rezurock’s EU authorization gives Sanofi a broader regulatory platform, while ruxolitinib, ECP, conventional immunosuppression, and country-specific hospital practices remain important comparators. Manufacturers must secure pricing and reimbursement separately across national health systems.

 

Prevention Could Reduce Future Treatment Demand

The FDA approved Tregzi, Orca Bio’s regulatory T-cell-based transplant product, on June 30, 2026, for eligible adults receiving matched-donor transplantation with a myeloablative regimen. Tregzi is used during transplantation to improve chronic-GVHD-free survival rather than to treat established disease.

At one year, 78% of Tregzi recipients achieved chronic-GVHD-free survival compared with 38.4% after standard transplantation. Serious chronic GVHD developed in 12.6% of Tregzi recipients versus 44% in the control group after accounting for death as a competing risk. Adoption in matched-donor transplant programs could reduce the future number of patients requiring chronic-GVHD drugs, infusions, and photopheresis.

Treatment demand will remain substantial because Tregzi does not cover every donor type, conditioning approach, transplant center, or existing GVHD patient. Unrelated, mismatched, haploidentical, and other transplantation pathways will continue to produce acute and chronic disease risk.

 

Commercial Outlook

Steroid-refractory acute disease, moderate-to-severe chronic disease, and patients progressing through several treatment lines will remain the principal revenue-generating populations. Oral medicines will compete through outpatient convenience and procedure avoidance. Infused biologics will rely on differentiated clinical activity and recurring dosing. Cellular therapies will depend on high response value, manufacturing reliability, center readiness, and reimbursement for multi-infusion courses.

Earlier-line expansion offers the largest opportunity for established branded products. Moving a therapy from third-line chronic disease into second-line treatment can materially increase eligible patient numbers. Adult expansion could have a similar effect for Ryoncil in acute GVHD.

Improved prophylaxis and preventive cell products may reduce disease incidence in selected transplant settings. Rising allogeneic transplant activity, longer post-transplant survival, and persistent steroid failure will continue to generate new treatment demand. Suppliers that demonstrate durable organ-level response, lower corticosteroid exposure, reduced hospital resource use, and payer-acceptable total costs will hold the strongest position.

 

Graft-versus-Host Disease Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.17 Billion
Revenue Forecast in 2032	USD 5.29 Billion
Overall Growth Rate	CAGR of 7.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Modality, By Line of Therapy, By Route of Administration, By Distribution Channel, By Geography
By Disease Type	Acute Graft-versus-Host Disease, Chronic Graft-versus-Host Disease
By Treatment Modality	Systemic Corticosteroids and Conventional Immunosuppressants, Targeted Oral Therapies, Infused Biologics, Cellular Therapies, Extracorporeal Photopheresis, Other Salvage Therapies
By Line of Therapy	First-Line Treatment, Second-Line Treatment, Third-Line and Later-Line Treatment
By Route of Administration	Oral, Intravenous, Extracorporeal
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Other Institutional Channels
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Market Drivers	Rising allogeneic hematopoietic cell transplantation activity Increasing prevalence of chronic graft-versus-host disease High unmet need among steroid-refractory patients
Customization Option	Available upon request